ahlam1399
04-21-2016, 03:29 PM
AbbVie gets option on early Argenx cancer drug for $40 million
(Reuters) - AbbVie has acquired an option on an early-stage immu**-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=MOVuneev4hk:qtmy1gYMQNE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=MOVuneev4hk:qtmy1gYMQNE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/MOVuneev4hk
(Reuters) - AbbVie has acquired an option on an early-stage immu**-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=MOVuneev4hk:qtmy1gYMQNE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=MOVuneev4hk:qtmy1gYMQNE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=MOVuneev4hk:qtmy1gYMQNE:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/MOVuneev4hk